Karolina Klusek

Karolina Klusek

Auto-generated profile, based on publicly available information

Karolina Klusek

Medical University of Lublin, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MKMaria Kiełbus
Maria Kiełbus
JOJulia OzięBło
Julia OzięBło
MKMagdalena Kijowska
Magdalena Kijowska
KKKarolina Klusek
Karolina Klusek
MBMichał Batory
Michał Batory
ASAleksandra Magdalena Skrzyniarz
Aleksandra Magdalena Skrzyniarz
Granulomatosis with polyangiitis (GPA) is a phenotypically heterogeneous form of ANCA-associated vasculitis characterized by two partially overlapping processes: extravascular granulomatous inflammation and necrotizing vasculitis of small- and medium-sized vessels. This dual pathobiology is particularly relevant in ocular disease, where some manifestations primarily reflect active vasculopathy and endothelial injury, whereas others result from locally destructive granulomatous inflammation extending from the sinonasal tract, orbit, sclera, and ocular adnexa. Ocular involvement is reported in approximately one quarter to one third of patients in contemporary pooled analyses, with higher rates in ophthalmology-based cohorts and in head-and-neck–limited disease. The most common manifestations include scleritis, episcleritis, orbital inflammatory mass or pseudotumor, peripheral ulcerative keratitis, and lacrimal system involvement; optic neuropathy, retinochoroidal inflammation, and visual loss are less frequent but potentially sight-threatening. The immunopathogenesis of ophthalmic GPA involves dysregulated B- and T-cell responses, ANCA-mediated neutrophil activation, neutrophil extracellular trap formation, complement amplification, and local tissue-destructive programs mediated by macrophages, plasma cells, fibroblasts, and matrix metalloproteinases. Rituximab remains the best-established biologic therapy, particularly for vasculitic ocular manifestations and peripheral ulcerative keratitis, although granulomatous orbital lesions may be relatively treatment-resistant. Future therapeutic strategies should target BAFF/APRIL/BCMA/TACI signaling, CD38-positive plasma cells, IL-6/IL-6R, IL-21/Tfh/ICOS pathways, Th17/IL-23 signaling, C5a/C5aR-mediated complement activation, NETosis, and monocyte-driven tissue invasion. A layered therapeutic approach combining control of ANCA-dependent inflammation with suppression of local granulomatous tissue destruction may be especially promising, although ocular-specific randomized trials remain lacking.

30 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KKKarolina Klusek
Karolina Klusek
MBMichał Batory
Michał Batory
JJJakub Jakubowski
Jakub Jakubowski
KKKarol Kraska
Karol Kraska
NKNadzieja Krasucka
Nadzieja Krasucka
MKMagdalena Kijowska
Magdalena Kijowska
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes mellitus and obesity, are increasingly being investigated for their potential relevance to psychiatric disorders. Accumulating preclinical and clinical evidence indicates that GLP-1 signaling extends beyond metabolic regulation and may influence central mechanisms implicated in mood regulation, motivational processing, compulsive reward-seeking, and interoceptive control. This review synthesizes current mechanistic, preclinical, clinical, and registry-based evidence concerning the possible role of GLP-1 RAs in psychiatry, with particular emphasis on major depressive disorder, substance use disorders, and eating disorders. The biological rationale for their psychiatric relevance is supported by evidence of GLP-1-mediated signaling through circumventricular organs, vagal–brainstem pathways, and selected central nervous system regions, including hypothalamic, hippocampal, and mesolimbic reward-related circuits. Proposed mechanisms include modulation of reward salience, attenuation of neuroinflammatory signaling, improvement of metabolic-inflammatory burden, and enhancement of neuroplastic processes. The clinical evidence remains heterogeneous and indication-specific. In depression, the most consistent findings relate to cognitive and motivational domains, particularly in patients with major depressive disorder and coexisting overweight or obesity, whereas broader evidence from metabolic trials suggests modest reductions in depressive symptoms without establishing disorder-specific antidepressant efficacy. In substance use disorders, alcohol use disorder currently represents the most advanced area of investigation, with semaglutide demonstrating favorable outcomes in a phase 2 trial, while exenatide showed no overall reduction in heavy drinking but reduced alcohol cue reactivity and suggested potential benefit in obese participants. Evidence for nicotine use disorder is mixed, and data concerning opioid and stimulant use disorders remain preliminary. In eating disorders, binge-eating phenotypes appear to be the most plausible therapeutic target, whereas evidence for bulimia nervosa is limited and anorexia-spectrum disorders raise important safety concerns due to appetite suppression and weight loss. Overall, the safety profile of GLP-1 RAs in psychiatric populations appears broadly consistent with their established metabolic use, with gastrointestinal adverse effects predominating; however, psychiatric monitoring remains advisable because observational safety data are not fully concordant. Current evidence supports further diagnosis-specific randomized controlled trials but does not yet justify routine psychiatric prescribing outside carefully selected clinical contexts or research settings.

24 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Batory
Michał Batory
JJJakub Jakubowski
Jakub Jakubowski
KKKarol Kraska
Karol Kraska
NKNadzieja Krasucka
Nadzieja Krasucka
AZAleksandra Zynkowska
Aleksandra Zynkowska
KKKarolina Klusek
Karolina Klusek
Perioperative hemorrhage remains an important clinical concern in gynecologic surgery, including hysterectomy, myomectomy, cesarean delivery, and oncologic procedures, as excessive blood loss may contribute to postoperative anemia, transfusion requirements, reoperation, prolonged hospitalization, and increased perioperative morbidity. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that reversibly binds to plasminogen and inhibits its conversion to plasmin, thereby reducing fibrin degradation and stabilizing formed clots. This review evaluates current evidence regarding the pharmacological properties, dosing strategies, efficacy, and safety profile of TXA in gynecologic surgical practice. Available randomized controlled trials and meta-analyses indicate that prophylactic administration of TXA, most commonly as a 1 g intravenous dose before surgical incision, significantly reduces intraoperative and postoperative blood loss across several gynecologic procedures. In benign hysterectomy, a large randomized controlled trial involving 332 patients demonstrated that intravenous TXA significantly decreased mean blood loss compared with placebo and reduced the incidence of bleeding exceeding 500 mL, as well as the need for reoperation due to postoperative hemorrhage. Evidence from myomectomy studies similarly suggests a clinically relevant reduction in perioperative blood loss, with meta-analytic data showing an average decrease of approximately 213 mL. In cesarean delivery, pooled data from randomized trials have shown that prophylactic TXA reduces total blood loss, transfusion rates, hemoglobin decline, and the need for additional uterotonic agents in both low- and high-risk patients. Comparable benefits have also been reported in selected gynecologic oncology procedures and after cervical conization. Importantly, across available studies, standard perioperative doses of TXA have not been associated with a significant increase in thromboembolic complications, although careful patient selection remains necessary, particularly in individuals with active thromboembolic disease or severe renal impairment. Overall, current evidence supports TXA as an effective, safe, and cost-efficient adjunct for reducing perioperative bleeding and transfusion requirements in gynecologic surgery. Future research should focus on defining optimal dosing and timing protocols for specific surgical subgroups, including extensive oncologic debulking procedures and complex endometriosis surgery, as well as evaluating long-term safety outcomes.

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
NBNatalia Bogumiłło
Natalia Bogumiłło
KMKrzysztof Mirkowski
Krzysztof Mirkowski
DŻDawid Żuraw
Dawid Żuraw
MKMagdalena Kijowska
Magdalena Kijowska
KKKarolina Klusek
Karolina Klusek
BBBartłomiej Baszun
Bartłomiej Baszun
Background. Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) are the two most frequent malignancies worldwide, and their incidence continues to rise with the ageing of the population. Although surgical excision remains the gold standard, radiotherapy — including brachytherapy — constitutes a valuable alternative in selected clinical situations, particularly in elderly patients and in tumours located in cosmetically or functionally sensitive areas. Aim. This narrative review aims to define the role of brachytherapy in the treatment of non-melanoma skin cancers, with emphasis on currently used techniques (surface, contact, mould-based, and interstitial methods, including Leipzig- and Valencia-type applicators and electronic brachytherapy), as well as on indications, patient selection, efficacy, and safety profile. Methods. The PubMed/MEDLINE and Google Scholar databases were searched for English-language publications, and 44 articles published between 2011 and 2025 were included and analysed descriptively. Conclusions. The available literature indicates that brachytherapy is an effective treatment strategy for selected non-melanoma skin cancers, providing high local control rates (reported between 71% and 99%), good cosmetic outcomes, and low toxicity. High dose conformity and effective sparing of healthy tissue make brachytherapy a valuable component of multidisciplinary skin cancer care.

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
KKKarol Kraska
Karol Kraska
NKNadzieja Krasucka
Nadzieja Krasucka
AZAleksandra Zynkowska
Aleksandra Zynkowska
ASAleksandra Magdalena Skrzyniarz
Aleksandra Magdalena Skrzyniarz
MKMaria Kiełbus
Maria Kiełbus
JJJakub Jakubowski
Jakub Jakubowski
This manuscript presents a focused narrative review with systematic literature identification of comparative evidence on faricimab versus aflibercept in adults with diabetic macular edema. The review prioritized randomized phase III evidence and selected only clinically decisive extension, post hoc, and real-world studies published from 2022 through 2025. The predefined PICO was: adults with DME; intervention faricimab; comparator aflibercept; outcomes best-corrected visual acuity, central subfield thickness, injection burden and durability, and safety. The core evidence base consisted of the YOSEMITE and RHINE randomized trials and their 2-year follow-up, supplemented by FDA regulatory documents and a small number of directly relevant post hoc and real-world studies. At year 1, faricimab achieved noninferior visual gains versus aflibercept in both trials, with numerically greater reductions in central subfield thickness. At year 2, visual acuity remained comparable, whereas anatomic outcomes and durability continued to favor faricimab, especially in the treat-and-extend arm, in which more than 60% of patients were on every-16-week dosing and approximately 80% were on every-12-week-or-longer dosing by week 96. Safety was broadly similar across randomized arms, although postmarketing retinal vasculitis warnings require continued pharmacovigilance. Direct real-world head-to-head evidence remained sparse; available switch studies suggest benefit primarily in selected aflibercept-refractory eyes. Overall, the present evidence supports faricimab as a clinically relevant alternative to aflibercept in DME when durability and anatomic control are prioritized, but not as a superior agent for letter gain alone.

21 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
DŻDawid Żuraw
Dawid Żuraw
MKMagdalena Kijowska
Magdalena Kijowska
KKKarolina Klusek
Karolina Klusek
KKKatarzyna Kulszo
Katarzyna Kulszo
MRMartyna Rynkowska
Martyna Rynkowska
KMKrzysztof Mirkowski
Krzysztof Mirkowski
Sleep disorders are among the most prevalent health problems in modern society and are increasingly recognized as an important risk factor for cardiovascular diseases. Growing evidence indicates that insufficient sleep duration, poor sleep quality, and conditions such as insomnia or obstructive sleep apnea may contribute to the development of arterial hypertension. Sleep plays a crucial role in maintaining systemic homeostasis by regulating neurological, endocrine, and metabolic functions. Sleep disturbances may lead to chronic activation of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, promoting inflammatory processes and impairing blood pressure regulation. An increasing body of evidence suggests that impaired sleep negatively affects overall health and may contribute to the development of multiple chronic diseases. Sleep disturbances frequently coexist with other cardiovascular risk factors, including chronic stress, obesity, physical inactivity, and unhealthy dietary habits, thereby amplifying their adverse effects. Persistent deterioration in sleep quality may result in metabolic, hormonal, and cardiovascular dysfunction, increasing the risk of long-term health complications and reducing quality of life. In light of current evidence, adequate sleep duration and quality should be considered essential components of hypertension prevention and public health promotion strategies.